<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646137</url>
  </required_header>
  <id_info>
    <org_study_id>Combined TACE and RF</org_study_id>
    <nct_id>NCT02646137</nct_id>
  </id_info>
  <brief_title>Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma</brief_title>
  <official_title>Comparison of Single Session Transarterial Chemoembolization Combined With Microwave Ablation or Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In
      recent years, transarterial chemoembolization, radio frequency ablation and microwave
      ablation have been accepted as treatment modalities for patients with surgically unresectable
      hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare between combination treatment with radiofrequency or microwave ablation followed
      by transarterial chemoembolization and performed in a single session.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with successful ablation</measure>
    <time_frame>3 months</time_frame>
    <description>The total number of patients with successful ablation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Transarterial chemoembolization (TACE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treated by transarterial chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation with TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency ablation combined with TACE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave ablation combined with TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microwave ablation combined with TACE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transarterial chemoembolization (TACE)</intervention_name>
    <description>TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles</description>
    <arm_group_label>Transarterial chemoembolization (TACE)</arm_group_label>
    <other_name>Transarterial chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation combined with TACE</intervention_name>
    <description>Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition</description>
    <arm_group_label>Radiofrequency ablation with TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave ablation combined with TACE</intervention_name>
    <description>Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis</description>
    <arm_group_label>Microwave ablation combined with TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child classification A or B.

          -  serum albumin ≥ 3 gm/L.

          -  serum bilirubin &lt; 2.5 mg/dL.

          -  platelet count ≥70,000 mm3.

          -  INR ≤ 1.6.

          -  serum creatinine &lt; 2 mg/dl.

          -  tumor size more than 4 cm and confined to one lobe of the liver.

        Exclusion Criteria:

          -  Patients with portal vein thrombosis.

          -  A technically inaccessible hepatic artery.

          -  Metastatic HCC.

          -  More than three lesions.

          -  lesions in close proximity to the portal vein (PV),inferior vena cava (IVC) or gall
             bladder were excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elshazly Sheta, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hepatology and gastroenterology dept.-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferial El-kalla, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology and Hepatology- Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Elgharib, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Interventional radiology - Ainshams university- Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelrahman kobtan, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>liver diseases dept.-Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Elhendawy, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>liver diseases dept.-Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>Hepatology and gastroenterology dept.-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Amer, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>Liver diseases and gastroenterology dept.-Tanta university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief M. Abd-Elsalam, Consultant</last_name>
    <phone>00201095159522</phone>
    <email>sherif_tropical@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Consultant liver and GIT diseases- Tanta university hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

